Key facts
- This page summarizes Bain Capital Life Sciences Investors, LLC's Form 4 filing for Xilio Therapeutics, Inc. (XLO).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2021, 19:33.
Bain Capital Life Sciences Investors, LLC - 08 Dec 2021 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- XLO
- Reported as of
- 08 Dec 2021
- Net transaction value
- +$410,161
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2021, 19:33:42 UTC
- Prior SEC filing
- 05 Nov 2021
- Next SEC filing
- 05 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- See Signatures Included in Exhibit 99.1
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bain Capital Life Sciences Investors, LLC filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 10 Dec 2021.
Change
- Previous filing in this sequence was filed on 05 Nov 2021.
- Current net transaction value: +$410,161.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XLO
transaction
Common Stock
Purchase
- Transaction value
- $129,474
- Shares
- +13,458
- Change %
- +0.49%
- Price
- $9.62
- Shares after
- 2,776,402
- Date
- 08 Dec 2021
- Ownership
- See footnotes
- Footnotes
- F1, F2, F6, F7, F8, F9, F10
XLO
transaction
Common Stock
Purchase
- Transaction value
- $39,485
- Shares
- +4,011
- Change %
- +0.14%
- Price
- $9.84
- Shares after
- 2,780,413
- Date
- 09 Dec 2021
- Ownership
- See footnotes
- Footnotes
- F1, F3, F6, F7, F8, F9, F10
XLO
transaction
Common Stock
Purchase
- Transaction value
- $208,564
- Shares
- +21,812
- Change %
- +0.78%
- Price
- $9.56
- Shares after
- 2,802,225
- Date
- 10 Dec 2021
- Ownership
- See footnotes
- Footnotes
- F1, F4, F6, F7, F8, F9, F10
XLO
transaction
Common Stock
Purchase
- Transaction value
- $32,638
- Shares
- +3,188
- Change %
- +0.11%
- Price
- $10.24
- Shares after
- 2,805,413
- Date
- 10 Dec 2021
- Ownership
- See footnotes
- Footnotes
- F1, F5, F6, F7, F8, F9, F10
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 10 footnotes
Footnote F1
On December 8, 2021, December 9, 2021 and December 10, 2021, BCLS II Investco, LP ("BCLS II Investco") purchased 13,458, 4,011 and 25,000 shares of the Issuer's common stock, respectively.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.41 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
Footnote F3
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.53 to $10.00, inclusive.
Footnote F4
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.07 to $10.00, inclusive.
Footnote F5
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.13 to $10.25, inclusive.
Footnote F6
Represents shares of the Issuer's common stock held by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities"). Following the completion of the transactions reported in footnote (1) to this Form 4, BCLS II, BCLS II Investco and BCIPLS each holds 1,348,682, 1,292,469 and 164,262 shares of the Issuer's common stock, respectively.
Footnote F7
Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of BCLS II. As a result, BCLSI II may be deemed to share voting and dispositive power with respect to the securities held by BCLS II. BCLSI II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Footnote F8
BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose manager is BCLS II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Footnote F9
Boylston Coinvestors, LLC is the general partner of BCIPLS.
Footnote F10
Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of BCLSI II and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
SEC remarks
Exhibit 99.1: Joint Filer Information